Tenofovir DF expanded access. Criteria for U.S. program.
An important new drug is now available through a special program for patients with advanced AIDS who have failed approved therapies.
D000225:Adenine / Q000031:analogs & derivatives* / Q000600:supply & distribution* / Q000627:therapeutic use; D017277:Drug Approval; D005060:Europe; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000600:supply & distribution* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D000068698:Tenofovir; D014481:United States; D014486:United States Food and Drug Administration
D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine